Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
What do Cochlear Limited's full-year results mean for its outlook?
⏸️ Investing
Cochlear Limited's 2014 dividend outlook
⏸️ Investing
4 top stocks to profit from a lower Australian dollar
⏸️ Investing
Should you buy Cochlear Limited?
⏸️ Investing
The 3 secret steps to ethical investing for profit
⏸️ Investing
An opportunity in 5 of the most shorted stocks on the ASX?
⏸️ Investing
3 reasons to keep holding your Cochlear Limited shares
⏸️ Investing
Investors still not convinced on Cochlear Limited
⏸️ Investing
Why Cochlear Limited shares spiked this morning
⏸️ Investing
7 steadfast dividend stocks to buy before you retire
⏸️ Investing
5 AWESOME biotechs that pay healthy dividends
⏸️ Investing
Why now is the perfect time to buy Cochlear Limited
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
